Drug delivery via nanocapsules

1. Drug Delivery via Nanocapsules

3. Held together by electrostatic forces

7. The calcium carbonate – compound microparticles are then encapsulated by a biodegradable shell.

8. The encapsulation process is very mild and requires no chemical treatment.

10. Encapsulation of Interferon Capture of Interferon using CaCO3 Shell material: Dextran sulfate sodium salt alternating with Poly-L-lysine hydrochloride. First and last layers are composed of dextran sulfate. Total number of layers is 7. Overall encapsulation efficiency is 90%-95%(weight to volume). Size of capsules is 4-5 microns(subject to clinical/delivery needs and can be adjusted accordingly). This is a preliminary trial. Shell material, thickness and capsule size may be altered to meet pharmacokinetic demands and requirements.

11. Safety of Nanoencapsulation Substances used for nanoencapsulation are biodegradable: Many are already FDA approved for human use in other applications. Subcutaneous injection: Results in degradation by macrophages. Local mild inflammation is noted on animal studies. No other significant reactions noted.

12. Safety of Nanoencapsulation Vero 1 cells after 60hours incubation: Synthetic capsule No degradation Dextran Sulfate and poly-Argininecapsule Degradation

13. Safety of Nanoencapsulation Mild tissue reaction. Good cellular uptake. Good capsule degradation.

14. Rationaleof Nanoencapsulation Main market-hepatitis C Potential for expansion to treatment of hepatitis B Renewed interest in interferon therapy for hepatitis B Limited treatment duration Potential for eAbseroconversion Potential for loss of sAg Large market internationally